If you work in pharmaceutical manufacturing, you have likely noticed a fundamental shift in the air. Following a wave of announcements in 2025 and early 2026, the United States is in the midst of a historic build-out of biologic manufacturing capacity.
Driven by demand for complex molecules—from monoclonal antibodies to cell and gene therapies—and bolstered by a focus on supply chain resilience, the industry’s biggest players are committing tens of billions of dollars to new facilities. This isn’t just about incremental expansion; it is about establishing new hubs in states like Georgia and Virginia, creating mega-sites designed for the next generation of medicine.
I have compiled a list of the 20 largest announced investments in new or expanded biologic facilities across the USA. The data is based on public disclosures from 2025 and early 2026.
Beyond the Table: The Major Capital Envelopes
While the table above focuses on specific facility announcements, it is crucial to recognize that several companies have authorized massive capital envelopes that will likely result in even more facilities in the coming years. These are the “checkbooks” to watch:
- Bristol Myers Squibb: Up to $70 Billion committed through 2030
- Novartis: $23 Billion committed over five years (specific sites rolling out)
- Pfizer: Approximately $20 Billion multi-year commitment
- Sanofi: Multi-billion dollar commitment through 2030
Analysis: What This Means for the Industry
For professionals in our field, this data tells a clear story:
- The Rise of the “Second Tier” Hubs: While New Jersey and Massachusetts remain strong, states like Georgia, Virginia, and Alabama are emerging as major manufacturing destinations. UCB’s $2 billion campus in Georgia was noted as the largest capital investment in Gwinnett County’s history
- Focus on “New” Modalities: It is not just about standard monoclonal antibodies anymore. We are seeing dedicated investments in cell therapy (J&J), radioligand therapy (Novartis), and antibody-drug conjugates (Merck) , indicating that manufacturing complexity is increasing
- API Onshoring: There is a distinct trend toward bringing Active Pharmaceutical Ingredient (API) manufacturing back to the US, particularly for high-demand metabolic drugs like weight-loss medicines (Lilly)
- Job Creation: These are not just capital investments; they represent significant workforce expansion. Merck’s Delaware site alone is expected to create over 500 permanent roles, with potential for 1,500 more, while UCB’s Georgia site will support 330 high-skilled permanent jobs
The next five years will be critical as these projects move from groundbreaking to GMP validation. For those of us in supply chain, engineering, and quality, this represents a massive shift in the landscape of US biopharmaceutical operations.
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
